[7] [9] Patients prescribed semaglutide should work closely with their healthcare team to monitor weight loss trajectory and adjust dietary intake accordingly
Monitor for persistent palpitations, chest discomfort, breathlessness, or dizziness, particularly during treatment initiation or dose escalation
Those with untreated hypothyroidism, polycystic ovary syndrome, or Cushing's syndrome may experience slower loss despite medication adherence
For those who are considering glutathione supplementation, being vigilant about these potential adverse effects ensures a safer experience
Research shows BPC-157 can protect tendons from damage caused by corticosteroid injections
Second, 7Percentage of patients experienced mild level I hypoglycemia with CagriSema compared to none with semaglutide [10]